Elsevier

Human Pathology

Volume 28, Issue 4, April 1997, Pages 459-464
Human Pathology

Original contribution
Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues

https://doi.org/10.1016/S0046-8177(97)90035-6Get rights and content

Abstract

Alterations in the von Hippel-Lindau (VHL) gene are correlated with a diverse group of neoplasms including hemangioblastoma, clear cell renal carcinoma (RCC), and pheochromocytoma. Molecular genetic studies suggest that VHL is a tumor-suppressor gene; correspondingly, reintroduction of a VHL complementary DNA (cDNA) into RCC cells inhibits their ability to form tumors in nude mice. Recently, it was discovered that the VHL gene product (pVHL) binds to two subunits of the transcription elongation complex Elongin (SIII), resulting in decreased activity of this complex in vitro. It is proposed that pVHL functions in vivo as a negative regulator of transcription elongation; however, the intracellular localization of pVHL has not been clearly delineated. Epitope-tagged pVHL has been observed in either the nucleus or the cytoplasm of cultured cells, depending on the density of the cell culture. In this article, the cellular localization of pVHL in normal and neoplastic human tissues is documented using three different monoclonal antibodies. Strong expression of pVHL was observed in the epithelial cells of all organs examined, particularly in renal tubules, and was exclusively cytoplasmic. Lesser degrees of staining, also cytoplasmic, were observed in other cell types. A variety of carcinomas (lung, prostate, colon, breast, bladder, and thyroid) showed strong cytoplasmic staining for pVHL including four of five sporadic clear cell RCC. Of the nonepithelial neoplasms examined, only one tumor, an embryonal rhabdomyosarcoma, failed to stain for pVHL. The findings establish widespread expression of VHL at the protein level and provide strong evidence that most, if not all, pVHL is localized to the cytoplasm of cells in vivo.

References (25)

  • T Shuin et al.

    Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas

    Cancer Res

    (1994)
  • K Foster et al.

    Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in nonfamilial clear cell renal cell carcinoma

    Hum Mol Genet

    (1994)
  • Cited by (101)

    • Optimal Specimen Handling and Ancillary Studies: Renal Neoplasia

      2013, Practical Renal Pathology: A Diagnostic Approach
    • The Phakomatoses

      2013, Emery and Rimoin's Principles and Practice of Medical Genetics
    • VHL deletion impairs mammary alveologenesis but is not sufficient for mammary tumorigenesis

      2010, American Journal of Pathology
      Citation Excerpt :

      We have shown that in the normal murine mammary gland, VHL expression increases over the course of pregnancy as MEC content increases and then decreases sharply at involution when MEC regress. These data are supported by previous observations that expression of VHL is primarily localized to the epithelium rather than the stroma.7,8,14 Conditional deletion of Vhl in response to either MMTV-Cre or Wap-Cre transgene expression reduced alveolar proliferation and secretory differentiation during the first round of pregnancy.

    • Role of SOCS and VHL Proteins in Neuronal Differentiation and Development

      2023, International Journal of Molecular Sciences
    View all citing articles on Scopus

    This is a US government work. There are no restrictions on its use.

    View full text